GlassScriptPhysician profile
Benjamin Yeboah
NPI 1174705636
$5,721.09
in general payments reported to CMS, 2019-2025
41 companies · $749 in 2025
The $749 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $1,151 · 2021: $870 · 2022: $624 · 2023: $319 · 2024: $567 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,481.41 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $570.76 | 2020-2025 | Fasenra, Breztri, Airsupra |
| Sunovion Pharmaceuticals INC. | $398.63 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $352.97 | 2019-2022 | |
| Amarin Pharma, INC. | $320.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $289.65 | 2019-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $253.03 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $237.69 | 2019-2020 | |
| Lilly USA, LLC | $212.81 | 2019-2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $192.08 | 2019-2025 | |
| Abbvie INC. | $168.19 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $124.80 | 2023 | Quviviq |
| Abiomed | $122.88 | 2024 | Impella |
| Lundbeck LLC | $109.45 | 2025 | Rexulti |
| Allergan, INC. | $100.67 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Yeboah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.